2015 launch possible as Gilead pursues sofosbuvir and combo in Japan
This article was originally published in Scrip
Executive Summary
Gilead Sciences expects to make the first approval filing in Japan for its investigational hepatitis C virus (HCV) therapy sofosbuvir sometime next year, with an approval possible in 2015 given a standard 12-month review time.